A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Clinical trial NCT05139017 · RECRUITING
Trial details
- NCT number
- NCT05139017
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-14
- Primary completion
- 2027-09-24
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.